119 related articles for article (PubMed ID: 31672785)
21. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
[TBL] [Abstract][Full Text] [Related]
22. Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape.
Ahmetlić F; Riedel T; Hömberg N; Bauer V; Trautwein N; Geishauser A; Sparwasser T; Stevanović S; Röcken M; Mocikat R
Cancer Immunol Res; 2019 Apr; 7(4):600-608. PubMed ID: 30894379
[TBL] [Abstract][Full Text] [Related]
23. Regulatory T cells in the immunotherapy of melanoma.
Ouyang Z; Wu H; Li L; Luo Y; Li X; Huang G
Tumour Biol; 2016 Jan; 37(1):77-85. PubMed ID: 26515336
[TBL] [Abstract][Full Text] [Related]
24. MiR-21 controls in situ expansion of CCR6⁺ regulatory T cells through PTEN/AKT pathway in breast cancer.
Hu Y; Wang C; Li Y; Zhao J; Chen C; Zhou Y; Tao Y; Guo M; Qin N; Ren T; Wen Z; Xu L
Immunol Cell Biol; 2015 Sep; 93(8):753-64. PubMed ID: 25735723
[TBL] [Abstract][Full Text] [Related]
25. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
[TBL] [Abstract][Full Text] [Related]
26. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
27. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
28. FOXA1
Liang J; Tian C; Zeng Y; Yang Q; Liu Y; Liu Y; Wu J; Hu Y; Gu F; Zhang K; Wang Y; Zhang Y; Liu L
Biochem Biophys Res Commun; 2019 Jun; 514(1):308-315. PubMed ID: 31036318
[TBL] [Abstract][Full Text] [Related]
29. Selective induction of delayed hypersensitivity T-effector and T-suppressor lymphocytes in vitro by haptenized bone marrow-derived macrophages.
Knop J; Malorny U; Macher E
Cell Immunol; 1984 Oct; 88(2):411-20. PubMed ID: 6237731
[TBL] [Abstract][Full Text] [Related]
30. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
31. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.
Brinkrolf P; Landmeier S; Altvater B; Chen C; Pscherer S; Rosemann A; Ranft A; Dirksen U; Juergens H; Rossig C
Int J Cancer; 2009 Aug; 125(4):879-86. PubMed ID: 19480009
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
33. Regulatory T cells in gastrointestinal tumors.
Raghavan S; Quiding-Järbrink M
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):489-501. PubMed ID: 21780896
[TBL] [Abstract][Full Text] [Related]
34. [Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
Shimazu Y; Nishikawa H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1057-61. PubMed ID: 25248887
[TBL] [Abstract][Full Text] [Related]
35. Induction of linked suppression in addition to the donor H-2 class I-specific unresponsiveness in recipient T cells by transfusing class I plus class II-disparate, but not class I alone-disparate, bone marrow cells.
Muraoka S
Cell Immunol; 1990 Jun; 128(1):261-76. PubMed ID: 1971530
[TBL] [Abstract][Full Text] [Related]
36. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer.
Xu L; Xu W; Qiu S; Xiong S
Clin Immunol; 2010 Jun; 135(3):466-75. PubMed ID: 20181533
[TBL] [Abstract][Full Text] [Related]
37. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
38. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
Ramacher M; Umansky V; Efferth T
Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
[TBL] [Abstract][Full Text] [Related]
39. Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity.
Nakagawa H; Sido JM; Reyes EE; Kiers V; Cantor H; Kim HJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6248-53. PubMed ID: 27185917
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
Rech AJ; Vonderheide RH
Ann N Y Acad Sci; 2009 Sep; 1174():99-106. PubMed ID: 19769742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
